Vaccine News and Research

Latest Vaccine News and Research

Two existing clinical stage clients expand development activities with Progenitor Cell Therapy

Progenitor Cell Therapy (PCT), an internationally recognized cell therapy services and development company, and a wholly-owned subsidiary of NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that two existing clinical stage biopharmaceutical corporate clients have chosen to expand their development activities with PCT.

18 Jul 2011

FDA files MedImmune's sBLA for quadrivalent intranasal nasal influenza vaccine, FluMist

MedImmune has received confirmation from the U.S. Food & Drug Administration (FDA) that the Agency has filed the Company's supplemental Biologics License Application (sBLA) for a quadrivalent (four-strain) version of FluMist® (Influenza Vaccine Live, Intranasal). The company submitted the sBLA early in the second quarter of this year.

18 Jul 2011

Researchers discover unexpected mode of action for vaccine adjuvant alum

The teams of Doctor Christophe Desmet and Professor Fabrice Bureau, of the Laboratory of Cellular and Molecular Physiology within the University of Liège's GIGA-Research centre, and of Professor Ken Ishii at the University of Osaka in Japan have just discovered an unexpected mode of action for the vaccine adjuvant alum.

18 Jul 2011

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

18 Jul 2011

Autism Speaks honors Scripps Research scientist with Weatherstone Fellowship

Autism Speaks, the nation's largest autism science and advocacy group, has awarded a two-year Dennis Weatherstone Pre-Doctoral Fellowship to Kristopher Nazor of The Scripps Research Institute.

16 Jul 2011

WHO says it is better prepared for influenza pandemic

"More than 100 public health experts have wrapped up a three-day meeting in Geneva to review a Global Action Plan for Influenza Vaccines that was developed in 2006, and to develop a strategic plan of action for the next five years," VOA News reports, noting that the WHO "says the world is better prepared for the next influenza pandemic than it was in the past".

16 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

Opinions about the CIA's ruse vaccination campaign in Pakistan

Health experts and writers continue to react to the CIA's use of a vaccine campaign to hunt Osama bin Laden.

15 Jul 2011

Vaccine and aid workers express anger over CIA plot to collect DNA through fake vaccine program

"Vaccine program workers, who sometimes struggle to gain public trust and governmental cooperation in the first place, are furious about the deception" of the CIA in establishing a fake vaccination program in Pakistan in an attempt to gather DNA from Osama bin Laden's family, ScienceInsider reports.

15 Jul 2011

Berks County's Department of Health advises public about possible measles exposure

The state Department of Health is advising the public of a possible case of measles exposure in Morgantown, Berks County.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

Non-invasive 'swine flu' breath test could help ease future vaccine shortages

A test, novel breath measuring the immune response to the H1N1 flu virus, could help to ease future vaccine shortages by identifying the people who have already been infected with the flu virus.

15 Jul 2011

Global health community reacts to CIA's faux vaccine operation in Pakistan

After the Guardian broke the story that the CIA organized a fake vaccination program in Pakistan in an effort to confirm the location of Osama bin Laden and obtain DNA from his family members, several writers and health experts reacted to the situation, noting the possible implications for health.

14 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

RXi expands intellectual property portfolio with additional NeuVax patents

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.

14 Jul 2011

Five-year research initiative to cure HIV disease

A team of AIDS experts at Johns Hopkins and other institutions have embarked on a joint five-year research initiative to cure HIV disease by finding ways to completely purge the virus from the body in people already successfully suppressing the virus with antiretroviral drug therapy.

14 Jul 2011

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

PharmAthene, Inc. announced today that it has achieved an important program milestone in its recombinant protective antigen (rPA) anthrax vaccine program and demonstrated 36 month stability of its rPA drug product candidate previously produced at Avecia Biologics Laboratories in the United Kingdom. The stability data were prepared utilizing a variety of analytical methods and a well characterized mouse challenge potency assay.

14 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

Patient-centered medical home boosts diabetes outcomes, health

A health-care delivery model called patient-centered medical home (PCMH) increased the percentage of diabetes patients who achieved goals that reduced their sickness and death rates, according to health researchers.

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011